RESUMO
Background & objectives Burden estimates of enteric fever are required to make policy decisions on introducing typhoid vaccine in India. Incidence, antimicrobial susceptibility, and out-of-pocket expenditure (OOPE) of enteric fever are estimated in Chandigarh, India. Methods A hybrid (facility and community-based) surveillance system was set up at a secondary care hospital to enrol patients above six months of age, hospitalized with fever, from a defined catchment population from May 2018 to March 2020. Blood samples were collected and cultured using an automated system (BD BACTECTM blood culture system). The Salmonella Typhi and S. Paratyphi isolates were characterized for antimicrobial susceptibility. OOPE was recorded after 14 and 28 days of discharge. Results Blood samples were collected from 97 per cent of the 1650 study participants enrolled. The incidence of enteric fever was 226.8 per 1,00,000 person-years (PY), severe typhoid fever 156.9 per 1,00,000 PY, and severe paratyphoid fever 69.9 per 1,00,000 PY. Salmonella was highly susceptible to ampicillin, azithromycin, and ceftriaxone (99.25%) and least susceptible to ciprofloxacin (11.3%). The OOPE due to hospitalization of individuals infected with S. Paratyphi [INR 8696.6 (USD 116)] was significantly higher than the individuals infected with S. Typhi [INR 7309 (USD 97.5), P=0.01], and among cases who were hospitalized for more than seven days [INR 12,251 (USD 163.3)] as compared with those with a stay of 3-7 days [INR 8038.2 (USD 107.2)] or less than three days [INR 5327.8 (USD 71), P<0.001]. Interpretation & conclusions There was a high incidence of enteric fever, high OOPE, and resistance to ciprofloxacin.
Assuntos
Ciprofloxacina , Salmonella typhi , Febre Tifoide , Humanos , Índia/epidemiologia , Febre Tifoide/epidemiologia , Febre Tifoide/microbiologia , Febre Tifoide/tratamento farmacológico , Salmonella typhi/efeitos dos fármacos , Salmonella typhi/patogenicidade , Incidência , Feminino , Masculino , Criança , Pré-Escolar , Ciprofloxacina/uso terapêutico , Ciprofloxacina/farmacologia , Adolescente , Adulto , Antibacterianos/uso terapêutico , Antibacterianos/farmacologia , Lactente , Testes de Sensibilidade Microbiana , Gastos em Saúde/estatística & dados numéricos , Febre Paratifoide/epidemiologia , Febre Paratifoide/microbiologia , Febre Paratifoide/tratamento farmacológico , Azitromicina/uso terapêutico , Ceftriaxona/uso terapêutico , Ceftriaxona/farmacologia , Salmonella paratyphi A/efeitos dos fármacos , Salmonella paratyphi A/patogenicidade , Ampicilina/uso terapêutico , Ampicilina/farmacologia , Pessoa de Meia-IdadeRESUMO
Listeria monocytogenes is a ubiquitous bacterium and opportunistic pathogen for immunocompromised patients. Peritoneal dialysis-related L. monocytogenes peritonitis is a rare clinical presentation, with a total of 23 cases reported to date and an overall mortality rate of 17.3%. The current report describes a case of peritoneal dialysis-related L. monocytogenes peritonitis in a woman in her 60s on long-term immunosuppressive therapies for a prior renal transplant. We treated this patient successfully with intraperitoneal ampicillin (125 mg/L in dialysate), in addition to intravenous ampicillin (1 g every 12 hours) for 10 days and subsequent oral amoxicillin 500 mg every 12 hours to complete a total 21-day course of therapy. This treatment regimen was informed by a literature review of pre-existing case studies, which demonstrated considerable variability in recommended antimicrobial dosing and frequency. A summary of this literature review is included in the current case report.
Assuntos
Ampicilina , Antibacterianos , Listeria monocytogenes , Listeriose , Diálise Peritoneal , Peritonite , Humanos , Feminino , Ampicilina/administração & dosagem , Ampicilina/uso terapêutico , Peritonite/microbiologia , Peritonite/tratamento farmacológico , Listeriose/tratamento farmacológico , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Listeria monocytogenes/isolamento & purificação , Diálise Peritoneal/efeitos adversos , Pessoa de Meia-Idade , Administração Intravenosa , Transplante de RimRESUMO
Perimyocarditis and myopericarditis are inflammatory conditions of the pericardium and myocardium, often of idiopathic or infectious etiology, with viral infections being the most common. Nonrheumatic streptococcal myopericarditis (NSM) is a rare condition that can mimic acute myocardial infarction. This case report presents a 22-year-old male with no prior medical history who developed NSM following a streptococcal pharyngitis infection. The patient presented with pleuritic chest pain, tightness, and decreased exercise tolerance. Laboratory studies revealed elevated troponin levels and positive Streptococcus G antigen. Treatment included ampicillin-sulbactam, colchicine, ibuprofen, and dexamethasone. The patient's symptoms resolved, and he was discharged with amoxicillin-clavulanate, colchicine, and ibuprofen.
Assuntos
Antibacterianos , Miocardite , Pericardite , Infecções Estreptocócicas , Humanos , Masculino , Pericardite/microbiologia , Pericardite/tratamento farmacológico , Pericardite/diagnóstico , Infecções Estreptocócicas/tratamento farmacológico , Infecções Estreptocócicas/diagnóstico , Infecções Estreptocócicas/complicações , Infecções Estreptocócicas/microbiologia , Miocardite/microbiologia , Miocardite/tratamento farmacológico , Miocardite/diagnóstico , Adulto Jovem , Antibacterianos/uso terapêutico , Faringite/microbiologia , Faringite/tratamento farmacológico , Ampicilina/uso terapêutico , Streptococcus/isolamento & purificação , Colchicina/uso terapêutico , Dor no Peito/etiologia , Ibuprofeno/uso terapêutico , Sulbactam/uso terapêuticoRESUMO
We present a case of Streptococcus iniae causing leptomeningitis, pyocephalus, and subdural empyema in an elderly male from India. There have been only a handful of cases of S. iniae infection reported worldwide, and none of them have been from India. In this case, an elderly diabetic patient presenting with backache, headache, and fever with severe neurological worsening was diagnosed with severe invasive S. iniae infection. He had hydrocephalus that needed ventriculoperitoneal shunting. The patient was treated with a prolonged course of intravenous ampicillin and vancomycin.
Assuntos
Antibacterianos , Empiema Subdural , Infecções Estreptocócicas , Humanos , Masculino , Infecções Estreptocócicas/diagnóstico , Infecções Estreptocócicas/tratamento farmacológico , Infecções Estreptocócicas/complicações , Infecções Estreptocócicas/microbiologia , Empiema Subdural/diagnóstico , Empiema Subdural/microbiologia , Empiema Subdural/tratamento farmacológico , Idoso , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagem , Vancomicina/administração & dosagem , Vancomicina/uso terapêutico , Meningites Bacterianas/diagnóstico , Meningites Bacterianas/tratamento farmacológico , Meningites Bacterianas/microbiologia , Streptococcus/isolamento & purificação , Ampicilina/uso terapêutico , Ampicilina/administração & dosagem , Hidrocefalia/etiologia , Hidrocefalia/diagnósticoRESUMO
BACKGROUND: Glycopeptides for ampicillin-susceptible Enterococcus faecalis/faecium bacteremia are readily prescribed depending on the severity of the condition. However, there is limited data on the outcomes of glycopeptide use compared to ampicillin-containing regimens for ampicillin-susceptible E. faecalis/faecium bacteremia. From an antibiotic stewardship perspective, it is important to determine whether the use of glycopeptides is associated with improved clinical outcomes in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. METHODS: This retrospective cohort study was conducted at a university-affiliated hospital between January 2010 and September 2019. We collected data from patients with positive blood cultures for Enterococcus species isolates. The clinical data of patients who received ampicillin-containing regimens or glycopeptides as definitive therapy for ampicillin-susceptible E. faecalis/faecium bacteremia were reviewed. Multivariate logistic regression analysis was performed to identify risk factors for 28-day mortality. RESULTS: Ampicillin-susceptible E. faecalis/faecium accounted for 41.2% (557/1,353) of enterococcal bacteremia cases during the study period. A total of 127 patients who received ampicillin-containing regimens (N = 56) or glycopeptides (N = 71) as definitive therapy were included in the analysis. The 28-day mortality rate was higher in patients treated with glycopeptides (19.7%) than in those treated with ampicillin-containing regimens (3.6%) (p = 0.006). However, in the multivariate model, antibiotic choice was not an independent predictor of 28-day mortality (adjusted OR, 3.7; 95% CI, 0.6-23.6). CONCLUSIONS: Glycopeptide use was not associated with improved mortality in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. This study provides insights to reduce the inappropriate use of glycopeptides in ampicillin-susceptible E. faecalis/faecium bacteremia treatment and promote antimicrobial stewardship.
Assuntos
Ampicilina , Antibacterianos , Bacteriemia , Enterococcus faecalis , Glicopeptídeos , Infecções por Bactérias Gram-Positivas , Sulbactam , Humanos , Estudos Retrospectivos , Bacteriemia/tratamento farmacológico , Bacteriemia/microbiologia , Bacteriemia/mortalidade , Ampicilina/uso terapêutico , Ampicilina/farmacologia , Masculino , Feminino , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Enterococcus faecalis/efeitos dos fármacos , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Infecções por Bactérias Gram-Positivas/microbiologia , Infecções por Bactérias Gram-Positivas/mortalidade , Idoso , Pessoa de Meia-Idade , Glicopeptídeos/uso terapêutico , Glicopeptídeos/farmacologia , Sulbactam/uso terapêutico , Sulbactam/farmacologia , Resultado do Tratamento , Testes de Sensibilidade Microbiana , Idoso de 80 Anos ou maisRESUMO
BACKGROUND: Listeria monocytogenes brain abscess is a rare phenomenon that is common in immunocompromised patients. Streptococcus equinus brain abscess has never been reported in the literature to our knowledge. In this case report, we describe a case of brain abscess secondary to Listeria monocytogenes and Streptococcus equinus in an immunocompetent patient with transient low CD4 count. CASE PRESENTATION: A 27-year-old white, male patient, previously healthy, nonalcoholic, and occasional smoker, presented to the emergency department for confusion and headache. The patient was found to have a left parietal abscess, which was drained and the fluid was sent for culture. Culture grew Listeria monocytogenes and Streptococcus equinus. The patient was treated with intravenous ampicillin followed by oral amoxicillin for a total of 6 weeks. The CD4 count was low initially. However, after the resolution of the infection, the CD4 count came back within normal range. Another brain magnetic resonance imaging was done that showed a significantly decreased hyperintensity within the left parietal subcortical white matter at the site of surgery with significantly decreased enhancement and almost total resolution of the previous abscess. CONCLUSION: Transient low CD4 count is a rare phenomenon that exposes patients to unusual and atypical infections. Since low CD4 count is transient, patients treated promptly recover from their illness. Our patient developed a Listeria monocytogenes and Streptococcus equinus brain abscess, which is considered rare and has not been previously described in the literature to our knowledge.
Assuntos
Antibacterianos , Abscesso Encefálico , Listeria monocytogenes , Listeriose , Infecções Estreptocócicas , Humanos , Masculino , Abscesso Encefálico/microbiologia , Abscesso Encefálico/tratamento farmacológico , Listeria monocytogenes/isolamento & purificação , Adulto , Antibacterianos/uso terapêutico , Infecções Estreptocócicas/tratamento farmacológico , Infecções Estreptocócicas/microbiologia , Infecções Estreptocócicas/diagnóstico , Listeriose/tratamento farmacológico , Listeriose/diagnóstico , Listeriose/microbiologia , Imageamento por Ressonância Magnética , Ampicilina/uso terapêutico , Imunocompetência , Amoxicilina/uso terapêutico , Amoxicilina/administração & dosagemRESUMO
PURPOSE: Meconium-stained amniotic fluid (MSAF) often signifies colonization of the amniotic sac by microorganisms. This study investigated additional adverse obstetric outcomes associated with MSAF in deliveries complicated by maternal intrapartum fever (IF). METHODS: This retrospective study included all singleton pregnancies from 2014 to 2020, with intrapartum maternal fever ≥ 38 °C during a trial of labor. In accordance with departmental protocol, all patients received intravenous antibiotic therapy consisting of ampicillin and gentamicin in the absence of allergies to these medications. Subsequent antibiotic therapy was adjusted based on the culture results. Antibiotic treatment was discontinued postpartum after 48 h without fever. Swab cultures were obtained immediately postpartum from both the maternal and fetal sides of the placenta. Maternal and fetal outcomes, along with positive placental cultures, were compared between participants with MSAF&IF and those with clear amniotic fluid &IF (control group). RESULTS: In comparison to the control group (n = 1089), the MSAF&IF group (n = 264) exhibited significantly higher rates of cesarean delivery (CD) (p = 0.001), CD due to non-reassuring fetal heart rate (p = 0.001), and cord pH ≤ 7.1 (p = 0.004). Positive swab cultures from the placental maternal and fetal sides were more prevalent among the MSAF&IF group (23.1% vs. 17.6%, p = 0.041 and 29.2% vs. 22.9%, p = 0.032, respectively). Placental cultures yielding gastrointestinal pathogens and extended spectrum beta-lactamase were notably more common in the MSAF&IF group compared to controls (p = 0.023). However, there was no significant difference between groups regarding the rate of group B streptococcus positive placental cultures. CONCLUSIONS: Women experiencing IF and MSAF during labor face an elevated risk of CD compared to those with IF alone. The presence of MSAF heightens the risk of positive placental cultures, particularly with gastrointestinal and extended spectrum beta-lactamase pathogens.
Assuntos
Líquido Amniótico , Antibacterianos , Cesárea , Mecônio , Humanos , Feminino , Gravidez , Mecônio/microbiologia , Estudos Retrospectivos , Líquido Amniótico/microbiologia , Adulto , Cesárea/estatística & dados numéricos , Antibacterianos/uso terapêutico , Recém-Nascido , Febre , Placenta/microbiologia , Ampicilina/uso terapêutico , Complicações Infecciosas na Gravidez/microbiologia , Complicações Infecciosas na Gravidez/diagnóstico , Gentamicinas/uso terapêutico , Resultado da Gravidez , Complicações do Trabalho de Parto/microbiologia , Complicações do Trabalho de Parto/diagnóstico , Complicações do Trabalho de Parto/etiologiaRESUMO
Sepsis is a common disease with high morbidity and mortality among newborns in intensive care units world-wide. Gram-negative bacillary bacteria are the major source of infection in neonates. Gentamicin is the most widely used aminoglycoside antibiotic in empiric therapy against early-onset sepsis. However, therapy failure may result due to various factors. The purpose of this study was to identify predictors of gentamicin therapy failure in neonates with sepsis. This was a prospective cross-sectional study at the Neonatal Intensive Care Unit at Windhoek Central Hospital over a period of 5 months in 2019. Neonates received intravenous gentamicin 5 mg/kg/24 h in combination with either benzylpenicillin 100 000 IU/kg/12 h or ampicillin 50 mg/kg/8 h. Logistic regression modeling was performed to determine the predictors of treatment outcomes. 36% of the 50 neonates were classified as having gentamicin treatment failure. Increasing treatment duration by 1 day resulted in odds of treatment failure increasing from 1.0 to 2.41. Similarly, one unit increase in CRP increases odds of gentamicin treatment failure by 49%. The 1 kg increase in birthweight reduces the log odds of treatment failure by 6.848, resulting in 99.9% decrease in the odds of treatment failure. One unit increase in WBC reduces odds of gentamicin treatment failure by 27%. Estimates of significant predictors of treatment failure were precise, yielding odds ratios that were within 95% confidence interval. This study identified the following as predictors of gentamicin therapy failure in neonates: prolonged duration of treatment, elevated C-reactive protein, low birthweight, and low white blood cell count.
Assuntos
Antibacterianos , Gentamicinas , Unidades de Terapia Intensiva Neonatal , Falha de Tratamento , Humanos , Gentamicinas/uso terapêutico , Gentamicinas/administração & dosagem , Recém-Nascido , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagem , Estudos Transversais , Estudos Prospectivos , Feminino , Masculino , Unidades de Terapia Intensiva Neonatal/estatística & dados numéricos , Sepse Neonatal/tratamento farmacológico , Proteína C-Reativa/análise , Sepse/tratamento farmacológico , Sepse/mortalidade , Peso ao Nascer , Ampicilina/uso terapêutico , Ampicilina/administração & dosagemRESUMO
RATIONALE: Listeria monocytogenes (LM) is an important foodborne bacterium, and LM meningoencephalitis is rare in clinical practice, with poor prognosis in severe patients. It is prone to misdiagnosis in clinical practice. We first reported a case of severe LM meningoencephalitis with muscle lesions and evaluated the comprehensive condition. PATIENT CONCERNS: A 48-year-old man had a fever and was admitted to the neurology department due to dizziness, nausea, and vomiting for 20 days. DIAGNOSES: LM meningoencephalitis complicated with muscle lesions. INTERVENTIONS: We used moxifloxacin 0.4 g, qd, meropenem 2 g, q8h, and dexamethasone 10 mg, qd to reduce exudation and adhesion. Then due to consideration of side effects, we increased the dose of ampicillin by 2 g, q4h, stopped using meropenem and moxifloxacin, and turned to maintenance treatment with dexamethasone and ampicillin. We comprehensively managed his vital signs and physical organ functions, we also controlled some comorbidities. During the hospitalization period thereafter, we used intravenous anti-infection treatment with moxifloxacin 0.4 g, qd, ampicillin 0.5 g, q4h. OUTCOMES: Half a year later, the reexamination showed only protein elevation in cerebrospinal fluid and hydrocephalus in MRI. Afterward, the symptoms did not recur again. The patient recovered well after discharge. LESSONS: LM meningoencephalitis complicated with lower limb muscle lesions is clinically rare. This report focuses on relevant treatment plans, which provide value for the examination and comprehensive management of patients with LM infection in the future.
Assuntos
Antibacterianos , Tontura , Febre , Náusea , Vômito , Humanos , Masculino , Pessoa de Meia-Idade , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagem , Febre/etiologia , Tontura/etiologia , Vômito/etiologia , Náusea/etiologia , Meningoencefalite/tratamento farmacológico , Meningoencefalite/diagnóstico , Meningoencefalite/microbiologia , Moxifloxacina/uso terapêutico , Moxifloxacina/administração & dosagem , Dexametasona/uso terapêutico , Dexametasona/administração & dosagem , Listeria monocytogenes/isolamento & purificação , Ampicilina/uso terapêutico , Ampicilina/administração & dosagemRESUMO
Background: The optimal ampicillin-sulbactam dosing regimen for carbapenem-susceptible Acinetobacter baumannii isolates in critically ill trauma patients has not been clearly defined. One strategy to provide the adequate sulbactam dose includes high-dose continuous infusion. Case(s) Description: We present three cases of critically ill trauma patients with augmented renal clearance treated with high-dose ampicillin-sulbactam through an intravenous continuous infusion for ventilator-associated pneumonia. All A. baumannii isolates were susceptible to sulbactam with low minimum inhibitory concentrations. All achieved clinical cure at the end of therapy and no recurrent pneumonia was noted. No clinically substantial adverse effect attributable to ampicillin-sulbactam therapy occurred. Discussion: There is limited evidence to endorse high-dose, continuous infusion ampicillin-sulbactam for treatment of infections caused by carbapenem-susceptible A. baumannii. This report presents three critically ill trauma patients with augmented renal clearance that achieved positive clinical outcomes with higher doses of ampicillin-sulbactam administered through a continuous infusion.
Assuntos
Infecções por Acinetobacter , Acinetobacter baumannii , Ampicilina , Antibacterianos , Unidades de Terapia Intensiva , Sulbactam , Humanos , Acinetobacter baumannii/efeitos dos fármacos , Sulbactam/administração & dosagem , Sulbactam/uso terapêutico , Ampicilina/administração & dosagem , Ampicilina/uso terapêutico , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Masculino , Infecções por Acinetobacter/tratamento farmacológico , Infecções por Acinetobacter/microbiologia , Pessoa de Meia-Idade , Adulto , Carbapenêmicos/administração & dosagem , Carbapenêmicos/farmacologia , Feminino , Testes de Sensibilidade Microbiana , Infusões Intravenosas , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Pneumonia Associada à Ventilação Mecânica/microbiologia , Resultado do Tratamento , Estado Terminal , Ferimentos e Lesões/complicações , Ferimentos e Lesões/tratamento farmacológico , Ferimentos e Lesões/microbiologia , IdosoRESUMO
This is a protocol for PPROM-AZM Study, phase II, nonblinded, randomized controlled trial. Bronchopulmonary dysplasia (BPD) at a postmenstrual age of 36 weeks (BPD36) is often observed in infants with preterm premature rupture of the membranes (pPROM). A regimen of ampicillin (ABPC) intravenous infusion for 2 days and subsequent amoxicillin (AMPC) oral administration for 5 days plus erythromycin (EM) intravenous infusion for 2 days followed by EM oral administration for 5 days is standard treatment for pPROM. However, the effect on the prevention of moderate/severe BPD36 using the standard treatment has not been confirmed. Recently, it is reported that ampicillin/sulbactam (ABPC/SBT) plus azithromycin (AZM) was effective for the prevention of moderate/severe BPD36 in pPROM patients with amniotic infection of Ureaplasma species. Therefore, our aim is to evaluate the occurrence rate of the composite outcome of "incidence rate of either moderate/severe BPD36 or intrauterine fetal death, and infantile death at or less than 36 weeks 0 days" comparing subjects to receive ABPC/SBT for 14 days plus AZM for 14 days (intervention group) and those to receive ABPC/SBT for 14 days plus EM for 14 days (control group), in a total of 100 subjects (women with pPROM occurring at 22-27 weeks of gestation) in Japan. The recruit of subjects was started on April 2022, and collection in on-going. We also investigate the association between the detection of Ureaplasma species and occurrence of BPD36. In addition, information on any adverse events for the mother and fetus and serious adverse events for infants are collected during the observation period. We allocate patients at a rate of 1:1 considering two stratification factors: onset of pPROM (22-23 or 24-27 weeks) and presence/absence of a hospital policy for early neonatal administration of caffeine. Trial registration: The trial number in the Japan Registry of Clinical Trials is jRCTs031210631.
Assuntos
Ampicilina , Antibacterianos , Azitromicina , Displasia Broncopulmonar , Eritromicina , Ruptura Prematura de Membranas Fetais , Adulto , Feminino , Humanos , Recém-Nascido , Gravidez , Amoxicilina/uso terapêutico , Amoxicilina/administração & dosagem , Ampicilina/administração & dosagem , Ampicilina/uso terapêutico , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Azitromicina/administração & dosagem , Azitromicina/uso terapêutico , Displasia Broncopulmonar/prevenção & controle , Displasia Broncopulmonar/tratamento farmacológico , Quimioterapia Combinada , Eritromicina/uso terapêutico , Eritromicina/administração & dosagem , Ruptura Prematura de Membranas Fetais/tratamento farmacológico , Idade Gestacional , Japão/epidemiologia , Sulbactam/administração & dosagem , Sulbactam/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Estudos Multicêntricos como Assunto , Ensaios Clínicos Fase II como AssuntoAssuntos
Aerossóis , Ampicilina , Antibacterianos , Recidiva , Humanos , Ampicilina/administração & dosagem , Ampicilina/uso terapêutico , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Administração por Inalação , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/complicações , Masculino , FemininoRESUMO
Microbial colonization and development of infections in wounds is a sign of chronicity. The prevailing approach to manage and treat these wounds involves dressings. However, these often fail in effectively addressing infections, as they struggle to both absorb exudates and maintain optimal local moisture. The system here presented was conceptualized with a three-layer design: the outer layer made of a fibrous polycaprolactone (PCL) film, to act as a barrier for preventing microorganisms and impurities from reaching the wound; the intermediate layer formed of a sodium alginate (SA) hydrogel loaded with ampicillin (Amp) for fighting infections; and the inner layer comprised of a fibrous film of PCL and polyethylene glycol (PEG) for facilitating cell recognition and preventing wound adhesion. Thermal evaluations, degradation, wettability and release behavior testing confirmed the system resistance overtime. The sandwich demonstrated the capability for absorbing exudates (≈70 %) and exhibited a controlled release of Amp for up to 24 h. Antimicrobial testing was performed against Staphylococcus aureus and Escherichia coli, as representatives of Gram-positive and Gram-negative bacteria: >99 % elimination of bacteria. Cell cytotoxicity assessments showed high cytocompatibility levels, confirming the safety of the proposed sandwich system. Adhesion assays confirmed the system ease of detaching without mechanical effort (0.37 N). Data established the efficiency of the sandwich-like system, suggesting promising applications in infected wound care.
Assuntos
Alginatos , Antibacterianos , Escherichia coli , Poliésteres , Staphylococcus aureus , Infecção dos Ferimentos , Alginatos/química , Infecção dos Ferimentos/tratamento farmacológico , Infecção dos Ferimentos/microbiologia , Staphylococcus aureus/efeitos dos fármacos , Escherichia coli/efeitos dos fármacos , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Antibacterianos/química , Antibacterianos/administração & dosagem , Poliésteres/química , Ampicilina/farmacologia , Ampicilina/uso terapêutico , Ampicilina/química , Humanos , Hidrogéis/química , Polietilenoglicóis/química , Animais , Bandagens , Testes de Sensibilidade Microbiana , Camundongos , Cicatrização/efeitos dos fármacosRESUMO
Urinary tract infections caused by Aerococcus urinae have rarely been reported in children, and the clinical characteristics remain unclear. We reviewed medical records of children whose urine cultures grew A. urinae (≥104 CFU/mL) at a tertiary children's hospital in Tokyo, Japan. We found 17 pediatric patients in a review of 22,769 urine cultures between June 2006 and May 2022. The median age of 17 patients was 10.7 years (IQR 8-13 years), and males represented 76.5 % of the patients. Sixteen patients (94.1 %) had underlying urological conditions (neurogenic bladder, vesicoureteral reflux, urethral stenosis, bladder exstrophy, or urinary catheterization). The chief symptoms were fever (35.3 %), malodorous urine (23.5 %), nausea (11.8 %), and back pain (5.9 %). Ten patients were asymptomatic. Pyelonephritis was diagnosed in five male patients. All of them had underlying abnormal conditions of the bladder, and two had malodorous urine. All patients had favorable outcomes after 10-14 days of ampicillin/amoxicillin-based antimicrobial therapy.
Assuntos
Aerococcus , Antibacterianos , Infecções Urinárias , Humanos , Masculino , Infecções Urinárias/microbiologia , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/diagnóstico , Infecções Urinárias/urina , Aerococcus/isolamento & purificação , Aerococcus/efeitos dos fármacos , Feminino , Criança , Adolescente , Antibacterianos/uso terapêutico , Estudos Retrospectivos , Infecções por Bactérias Gram-Positivas/urina , Infecções por Bactérias Gram-Positivas/microbiologia , Infecções por Bactérias Gram-Positivas/diagnóstico , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Pielonefrite/microbiologia , Pielonefrite/urina , Pielonefrite/tratamento farmacológico , Pielonefrite/diagnóstico , Ampicilina/uso terapêutico , Japão/epidemiologia , Amoxicilina/uso terapêuticoRESUMO
Introduction: Peritoneal dialysis (PD) - associated peritonitis is a serious complication of peritoneal dialysis (PD). The 2022 International Society of Peritoneal Dialysis (ISPD) guidelines do not recommend intraperitoneal (IP) ampicillin for treatment of Enterococcal PD - associated peritonitis. To date, there is no in vivo data to support use of IP ampicillin for the treatment of Enterococcus faecalis. Case Description: A 69-year-old man with a past medical history of end stage kidney disease (ESKD) requiring continuous cycling peritoneal dialysis (CCPD) was admitted to the hospital and treated for peritonitis with E. faecalis. The patient's CCPD prescription was 2.5% Dianeal with 5 total exchanges. IP ampicillin was added to the first 4 exchanges and additional ampicillin was added to the last fill. The patient successfully completed the treatment course with clinical cure. Discussion: The use of IP ampicillin for E. faecalis peritonitis is controversial and previously lacked compelling clinical evidence for or against its use. This case demonstrates treatment of peritonitis using a modified dosing strategy with ampicillin added to each CCPD exchange and last fill. The loss of ampicillin antimicrobial activity reported in vitro with E. faecalis was not supported by this case.
Assuntos
Ampicilina , Antibacterianos , Enterococcus faecalis , Infecções por Bactérias Gram-Positivas , Peritonite , Humanos , Ampicilina/administração & dosagem , Ampicilina/uso terapêutico , Enterococcus faecalis/efeitos dos fármacos , Idoso , Peritonite/tratamento farmacológico , Peritonite/microbiologia , Masculino , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Diálise Peritoneal/efeitos adversos , Falência Renal Crônica/terapiaRESUMO
BACKGROUND: Severe infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have been reported increasingly over the past few years. Many in-vivo and in-vitro studies have suggested a possible role of intravenous fosfomycin for the treatment of CRAB infections. METHODS: This multi-centre, retrospective study included patients treated with intravenous fosfomycin for severe infections caused by CRAB admitted consecutively to four hospitals in Italy from December 2017 to December 2022. The primary goal of the study was to evaluate the risk factors associated with 30-day mortality in the study population. A propensity score matched analysis was added to the model. RESULTS: One hundred and two patients with severe infections caused by CRAB treated with an intravenous fosfomycin-containing regimen were enrolled in this study. Ventilator-associated pneumonia (VAP) was diagnosed in 59% of patients, primary bacteraemia in 22% of patients, and central-venous-catheter-related infection in 16% of patients. All patients were treated with a regimen containing intravenous fosfomycin, mainly in combination with cefiderocol (n=54), colistin (n=48) or ampicillin/sulbactam (n=18). Forty-eight (47%) patients died within 30 days. Fifty-eight (57%) patients experienced clinical therapeutic failure. Cox regression analysis showed that diabetes, primary bacteraemia and a colistin-containing regimen were independently associated with 30-day mortality, whereas adequate source control of infection, early 24-h active in-vitro therapy, and a cefiderocol-containing regimen were associated with survival. A colistin-based regimen, A. baumannii colonization and primary bacteraemia were independently associated with clinical failure. Conversely, adequate source control of infection, a cefiderocol-containing regimen, and early 24-h active in-vitro therapy were associated with clinical success. CONCLUSIONS: Different antibiotic regimens containing fosfomycin in combination can be used for treatment of severe infections caused by CRAB.
Assuntos
Infecções por Acinetobacter , Acinetobacter baumannii , Administração Intravenosa , Antibacterianos , Carbapenêmicos , Fosfomicina , Pneumonia Associada à Ventilação Mecânica , Sulbactam , Humanos , Fosfomicina/uso terapêutico , Fosfomicina/administração & dosagem , Acinetobacter baumannii/efeitos dos fármacos , Infecções por Acinetobacter/tratamento farmacológico , Infecções por Acinetobacter/mortalidade , Infecções por Acinetobacter/microbiologia , Estudos Retrospectivos , Masculino , Feminino , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagem , Idoso , Pessoa de Meia-Idade , Carbapenêmicos/uso terapêutico , Sulbactam/uso terapêutico , Sulbactam/administração & dosagem , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Pneumonia Associada à Ventilação Mecânica/microbiologia , Pneumonia Associada à Ventilação Mecânica/mortalidade , Colistina/uso terapêutico , Colistina/administração & dosagem , Itália , Ampicilina/uso terapêutico , Ampicilina/administração & dosagem , Cefiderocol , Idoso de 80 Anos ou mais , Quimioterapia Combinada , Bacteriemia/tratamento farmacológico , Bacteriemia/microbiologia , Bacteriemia/mortalidade , Farmacorresistência Bacteriana MúltiplaRESUMO
AIM: To compare the prophylactic efficacy of ampicillin and clindamycin against vertical transmission of group B Streptococcus from mothers to their infants by evaluating the rates of group B Streptococcus colonisation. METHODS: We retrospectively extracted data for mothers who delivered at Showa University Northern Yokohama Hospital between 1 October 2017 and 31 March 2021 and tested positive for antepartum group B Streptococcus, and their infants. The chi-square test was used to compare the rates of group B Streptococcus colonisation, sepsis, and meningitis. We conducted a multivariate logistic regression analysis, including the time interval between membrane rupture and delivery, chorioamnionitis, and maternal intrapartum fever (≥38.0°C). RESULTS: Two hundred fifty-nine mothers and their infants were eligible. Ampicillin and clindamycin were administered to 150 and 109 mothers, respectively. In the ampicillin and clindamycin groups, 12.0% (18/150) and 37.6% (41/109) infants were group B Streptococcus positive, respectively. The rate of group B Streptococcus colonisation among infants was significantly lower in the ampicillin group (p < 0.001). Multivariate regression analysis showed similar results (p < 0.001). No sepsis or meningitis cases were observed in either group. CONCLUSION: Prophylactic efficacy of clindamycin against the vertical transmission of group B Streptococcus is lower than that of ampicillin.
Assuntos
Ampicilina , Antibacterianos , Clindamicina , Transmissão Vertical de Doenças Infecciosas , Infecções Estreptocócicas , Streptococcus agalactiae , Humanos , Ampicilina/uso terapêutico , Clindamicina/uso terapêutico , Feminino , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Estudos Retrospectivos , Infecções Estreptocócicas/prevenção & controle , Infecções Estreptocócicas/transmissão , Gravidez , Antibacterianos/uso terapêutico , Recém-Nascido , Adulto , Antibioticoprofilaxia/métodos , Complicações Infecciosas na Gravidez/prevenção & controle , Complicações Infecciosas na Gravidez/tratamento farmacológicoRESUMO
BACKGROUND: Rat bite fever is a rare but potentially fatal bacterial zoonosis. The symptoms can be unspecific, but severe sepsis can be associated with involvement of different organs. CASE REPORT: A 27-year-old homeless man presented with fever, suspected meningitis, acute renal failure, unclear skin lesions as well as joint problems and muscular pain. Bite wounds were not detected. Meningitis could be excluded after lumbar puncture, and there was no evidence of endocarditis as the cause of the skin lesions. After 72â¯h, growth of Streptobacillus moniliformis in blood cultures was detected. Clinical symptoms were compatible with the diagnosis of rat bite fever. Calculated antibiosis with ampicillin sulbactam and doxycycline led to regression of the symptoms. CONCLUSION: Rat bite fever poses a diagnostic challenge due unspecific symptoms, diverse differential diagnostic options, and challenging microbiological detection. Patient history is of the utmost importance. Due to the rarity of the disease, this case report is intended to raise awareness.
Assuntos
Febre por Mordedura de Rato , Streptobacillus , Zoonoses , Masculino , Adulto , Febre por Mordedura de Rato/diagnóstico , Febre por Mordedura de Rato/tratamento farmacológico , Febre por Mordedura de Rato/microbiologia , Humanos , Animais , Streptobacillus/isolamento & purificação , Zoonoses/diagnóstico , Zoonoses/microbiologia , Zoonoses/transmissão , Antibacterianos/uso terapêutico , Doxiciclina/uso terapêutico , Diagnóstico Diferencial , Ratos , Sulbactam/uso terapêutico , Sulbactam/administração & dosagem , Ampicilina/uso terapêuticoRESUMO
INTRODUCTION: Haemophilus influenzae (HI) is an exceedingly rare cause of infective endocarditis (IE). CASE PRESENTATION/METHODS: We present a case of a 90-year-old female diagnosed with HI-IE involving the native tricuspid valve in the absence of traditional risk factors for right-sided endocarditis. She was treated with a 5-week course of IV Ampicillin from negative cultures and suffered no complications. We also conducted a thorough literature review through PubMed and Google Scholar, which yielded a mere 15 reported cases of HI-IE. RESULTS: Fourteen of the reported HI-IE cases included epidemiological data, showing no gender predominance. The mean age of the subjects was 39.5, with the mitral valve being the most implicated (64%) and tricuspid valve involvement being rare (21%). CONCLUSION: Native tricuspid valve IE is an uncommon entity, especially in the absence of IV drug use. Haemophilus influenzae is an extremely rare cause of IE, with a literature review showing merely 15 reported cases. This article cites the 16th case of HI-IE published in the literature.
Assuntos
Antibacterianos , Endocardite Bacteriana , Infecções por Haemophilus , Haemophilus influenzae , Humanos , Feminino , Infecções por Haemophilus/tratamento farmacológico , Infecções por Haemophilus/microbiologia , Infecções por Haemophilus/diagnóstico , Idoso de 80 Anos ou mais , Haemophilus influenzae/isolamento & purificação , Antibacterianos/uso terapêutico , Endocardite Bacteriana/microbiologia , Endocardite Bacteriana/tratamento farmacológico , Endocardite Bacteriana/diagnóstico , Ampicilina/uso terapêutico , Valva Tricúspide/microbiologia , Valva Tricúspide/diagnóstico por imagemRESUMO
OBJECTIVE: To investigate the clinical characteristics and prognostic risk factors for Klebsiella pneumoniae bloodstream infections in immunocompetent patients. METHODS: The study included patients with K. pneumoniae bloodstream infection treated in Zhongda Hospital from June 2016 to June 2021. Clinical data and antibiotic susceptibility test results were retrospectively collected and analyzed. Independent risk factors for mortality were screened using the chi-square test and multivariate logistic regression. RESULTS: A total of 152 patients were included in the analysis. In our cohort, 77.6% of patients were older than 60 years, and 80.9% of them had community-acquired infections. The most common complications were type 2 diabetes, hypertension, and stroke sequelae. The proportion of patients with septic shock or abscesses was 34.9% and 25.7%, respectively. There were significant differences in the site of infection, septic shock, and serum levels of procalcitonin, hypersensitive C-reactive protein, D-dimer, creatinine, and lactic acid between survivors and non-survivors (p < 0.05). Multivariate regression analysis showed that hospital-acquired infections, septic shock, length of hospital stay, and creatinine levels were independent risk factors for mortality. Antibiotic susceptibility test results indicated that clinical outcomes varied depending on bacterial sensitivity to ampicillin/sulbactam. DISCUSSION: Klebsiella pneumoniae is a common community-acquired and hospital-acquired bacteria and usually infects older people with complications such as diabetes. Nosocomial infections, length of stay, septic shock, and renal insufficiency are potentially associated with poor prognosis. Bacterial susceptibility to ampicillin/sulbactam affects prognosis.